Valuation UCB

Stocks

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-06-17 EDT			5-day change	1st Jan Change
252.40 ^EUR	+0.96%		-4.54%	+5.78%

06-17	UCB Publishes Data Demonstrating Positive Impact Of Kygevvi In Patients With Thymidine Kinase 2 Deficiency	CI
06-17	UCB SA completed the acquisition of Candid Therapeutics, Inc. from Vida Ventures Advisors, LLC and Two River Group Holdings, LLC.	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,947	13,973	14,969	36,464	45,333	48,047	-	-
Change	-	-26.25%	7.12%	143.6%	24.32%	5.99%	-	-
Enterprise Value (EV) ¹	19,807	15,973	17,146	37,918	45,326	46,940	44,980	42,545
Change	-	-19.36%	7.34%	121.15%	19.54%	3.56%	-4.17%	-5.41%
P/E	17.9x	33.4x	44.8x	34.3x	29.1x	27.2x	20.9x	16.7x
PBR	2.32x	1.58x	1.67x	3.64x	-	4.09x	3.5x	2.87x
PEG	-	-0.6x	-2.2x	0x	0.6x	2.1x	0.7x	0.7x
Capitalization / Revenue	3.28x	2.53x	2.85x	5.93x	5.86x	5.64x	4.98x	4.45x
EV / Revenue	3.43x	2.9x	3.26x	6.16x	5.86x	5.51x	4.66x	3.94x
EV / EBITDA	12.1x	12.7x	12.7x	25.7x	17.2x	16.1x	12.4x	9.76x
EV / EBIT	15x	23.7x	26.1x	45.4x	22.6x	20.3x	15x	11.5x
EV / FCF	15.6x	18.4x	38.5x	41.2x	24.6x	23.9x	17.4x	13.6x
FCF Yield	6.42%	5.43%	2.6%	2.43%	4.06%	4.19%	5.74%	7.36%
Dividend per Share ²	1.3	1.33	1.36	1.39	1.45	1.465	1.505	1.538
Rate of return	1.3%	1.81%	1.72%	0.72%	0.61%	0.58%	0.6%	0.61%
EPS ²	5.6	2.2	1.76	5.61	8.2	9.276	12.05	15.09
Distribution rate	23.2%	60.5%	77.3%	24.8%	17.7%	15.8%	12.5%	10.2%
Net sales ¹	5,777	5,517	5,252	6,152	7,741	8,526	9,651	10,787
EBITDA ¹	1,641	1,260	1,349	1,476	2,636	2,915	3,631	4,357
EBIT ¹	1,318	675	657	836	2,009	2,317	2,994	3,708
Net income ¹	1,058	418	343	1,065	1,558	1,740	2,310	2,866
Net Debt ¹	860	2,000	2,177	1,454	-7	-1,107	-3,067	-5,503
Reference price ²	100.35	73.56	78.90	192.20	238.60	252.40	252.40	252.40
Nbr of stocks (in thousands)	188,812	189,959	189,721	189,720	189,996	190,361	-	-
Announcement Date	2/24/22	2/22/23	2/28/24	2/27/25	2/24/26	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
UCB	26.98x	5.45x	15.6x	0.59%	55.22B
REGENERON PHARMACEUTICALS, INC.	15.92x	3.44x	9.28x	0.64%	62.54B
SAMSUNG BIOLOGICS CO.,LTD.	32.95x	11.15x	21.03x	-.--%	40.9B
CSL LIMITED	-48.34x	2.92x	8.61x	3.79%	35.99B
BIOGEN INC.	31.58x	3.43x	10.37x	-.--%	28.88B
MODERNA, INC.	-6.41x	8.8x	-5.38x	-.--%	21.98B
INCYTE CORPORATION	15.2x	2.66x	8.22x	-.--%	19.93B
INNOVENT BIOLOGICS, INC.	49.02x	5.22x	37.44x	-.--%	16.95B
SWEDISH ORPHAN BIOVITRUM AB	24.09x	4.99x	13.47x	-.--%	15.87B
BRIDGEBIO PHARMA, INC.	-30.63x	14.4x	-43.78x	-.--%	13.05B
Average	11.04x	6.24x	7.48x	0.5%	31.13B
Weighted average by Cap.	12.79x	5.71x	10.39x	0.67%